CliffBio
small molecule

MYDAYIS

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

Loss of exclusivityAugust 2029latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameMYDAYIS
Active ingredientAMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Strength6.25MG;6.25MG;6.25MG;6.25MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2017
Marketing statusRX

Listed patents

PatentExpiresType
8846100August 2029product
9173857May 2026use U-2025

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MYDAYIS patent cliff — loss of exclusivity August 2029 | CliffBio